Johnson & Johnson will restart shipments of its Covid-19 vaccine to Europe after the continent’s health agency concluded the benefits outweighed the risks even after it identified a “possible link” between the jab and rare blood clots.
The European Medicines Agency said on Tuesday that a rare combination of blood clots and low platelet count should be added to the list of side-effects from the J&J jab. However, it added that the overall benefits of the single-shot vaccine exceeded the risks of these reactions.
J&J said it would resume shipment of 200m vaccine doses to the EU, Norway and Iceland and update its information on the diagnosis and management of the “very rare adverse event”.
您已閱讀20%（693字），剩餘80%（2748字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。